Analyst Price Targets — KNSA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 30, 2026 10:10 am | Paul Choi | Goldman Sachs | $90.00 | $80.92 | TheFly | Kiniksa price target raised to $90 from $75 at Goldman Sachs |
| July 29, 2026 1:04 pm | — | Wedbush | $99.00 | $79.58 | TheFly | Kiniksa price target raised to $99 from $72 at Wedbush |
| July 29, 2026 11:16 am | Edward Nash | Canaccord Genuity | $98.00 | $79.44 | TheFly | Kiniksa price target raised to $98 from $64 at Canaccord |
| July 23, 2026 10:01 am | Paul Choi | Goldman Sachs | $75.00 | $62.44 | TheFly | Kiniksa price target raised to $75 from $60 at Goldman Sachs |
| July 13, 2026 10:25 am | — | Wells Fargo | $74.00 | $63.44 | TheFly | Kiniksa price target raised to $74 from $57 at Wells Fargo |
| June 29, 2026 11:53 am | — | Wedbush | $72.00 | $59.20 | TheFly | Kiniksa price target raised to $72 from $59 at Wedbush |
| April 29, 2026 11:42 am | — | Wedbush | $59.00 | $53.85 | TheFly | Kiniksa price target raised to $59 from $58 at Wedbush |
| April 28, 2026 5:03 pm | Roger Song | Jefferies | $71.00 | $53.80 | TheFly | Kiniksa price target raised to $71 from $58 at Jefferies |
| April 16, 2026 12:35 pm | — | Wedbush | $58.00 | $46.25 | TheFly | Kiniksa price target raised to $58 from $53 at Wedbush |
| February 19, 2026 10:35 am | — | Canaccord Genuity | $62.00 | $45.39 | TheFly | Kiniksa initiated with a Buy at Canaccord |
Latest News for KNSA
Kiniksa Pharmaceuticals International NASDAQ: KNSA said its commercialized recurrent pericarditis treatment ARCALYST continues to grow, while the company has begun a pivotal Phase 3 study of follow-on candidate KPL-387.
LONDON, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026 at 9:00 a.m. Eastern Time.
KNSA lifted 2026 ARCALYST sales guidance as Q2 revenue surged, while advancing KPL-387 into Phase 3 to support its next growth driver.
Kiniksa Pharmaceuticals International, plc (KNSA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Kiniksa Pharmaceuticals International, plc (KNSA) Q2 2026 Earnings Call Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for KNSA.
U.S. House Trading
No House trades found for KNSA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.